Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus

 Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at
       the 10th International Congress on Systemic Lupus Erythematosus

PR Newswire

HAYWARD, Calif., March 22, 2013

HAYWARD, Calif., March 22, 2013 /PRNewswire/ --Anthera Pharmaceuticals, Inc.
(Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious
diseases associated with inflammation and autoimmune disorders, today
announced its abstract entitled "Blisibimod, an Emerging Subcutaneous Biologic
Therapy for Patients with Active, Moderate-to-Severe Systemic Lupus
Erythematosus," has been selected as an oral presentation and will be
presented at the 10th International Congress on Systemic Lupus Erythematosus
by Dr. Morton Scheinberg, a rheumatologist at the Hospital Abreu Sodre
Pesquisa Clinica in Sao Paulo, Brazil, on April 20, 2013.

Additionally, a poster entitled "Clinical Experience in Latin America With
Blisibimod Amongst Subjects with Active, Moderate-to-Severe Systemic Lupus
Erythematosus: Data From The Phase 2b PEARL-SC Study," will be presented by
Dr. Scheinberg as part of the conferences Guided Poster Tours on April 19,
2013.

The poster will be available on www.anthera.com.

About Blisibimod and PEARL-SC

BAFF has been associated with a wide range of B-cell-mediated autoimmune
diseases, including systemic lupus erythematosus, vasculitis, IgA nephropathy,
immune thrombocytopenic purpura and others. Multiple clinical studies with
other BAFF antagonists recently have reported on BAFF inhibitors potential
positive role in treating lupus and rheumatoid arthritis. Anthera is advancing
its development of blisibimod, a selective inhibitor of BAFF, to expand its
potential clinical utility in autoimmune diseases. Blisibimod is a novel
fusion protein called a peptibody and is distinct from an antibody. Anthera
owns worldwide rights to blisibimod in all potential indications. The
PEARL-SC Phase 2 study was designed as a randomized, double-blind,
placebo-controlled, dose-ranging trial to evaluate the safety, tolerability
and efficacy of blisibimod plus standard of care, versus placebo plus standard
of care. A total of 547 patients with active SLE were randomized to receive
one of three different doses of blisibimod or placebo (100 mg weekly, 200 mg
weekly or 200 mg monthly) administered subcutaneously over a minimum 24-week
treatment period, in addition to standard-of-care therapy. The study was
conducted at multiple centers worldwide.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing
and commercializing products to treat serious diseases associated with
inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or
other non-historical matters, including statements that are preceded by,
followed by, or that include such words as "estimate," "intend," "anticipate,"
"believe," "plan," "goal," "expect," "project," or similar statements, are
forward-looking statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on Anthera's expectations as of the date of this press
release and are subject to certain risks and uncertainties that could cause
actual results to differ materially as set forth in Anthera's public filings
with the SEC, including Anthera's Annual Report on Form 10-K for the year
ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter
ended September 30, 2012. Anthera disclaims any intent or obligation to
update any forward-looking statements, whether because of new information,
future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or
510.856.5586.

SOURCE Anthera Pharmaceuticals, Inc.

Website: http://www.anthera.com
 
Press spacebar to pause and continue. Press esc to stop.